Shopping Cart

Remove All

Your shopping cart is currently empty

Proceed to checkout Continue shopping

M435-1279

Name: M435-1279
Brand: TargetMol
SKU: T9500
Rating: 4.5 (1 reviews)

😃Good

Catalog No. T9500Cas No. 1359431-16-5

M435-1279 is a UBE2T inhibitor that blocks UBE2T-mediated degradation of RACK1, thereby inhibiting the hyperactivation of the Wnt/β-catenin signaling pathway.

M435-1279

😃Good

Catalog No. T9500Cas No. 1359431-16-5

M435-1279 is a UBE2T inhibitor that blocks UBE2T-mediated degradation of RACK1, thereby inhibiting the hyperactivation of the Wnt/β-catenin signaling pathway.

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$31	6-8 weeks	6-8 weeks
5 mg	$73	6-8 weeks	6-8 weeks
10 mg	$116	6-8 weeks	6-8 weeks
25 mg	$223	6-8 weeks	6-8 weeks
50 mg	$333	6-8 weeks	6-8 weeks
100 mg	$470	6-8 weeks	6-8 weeks
200 mg	$662	6-8 weeks	6-8 weeks
1 mL x 10 mM (in DMSO)	$87	-	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Resource Download

Product Introduction

Bioactivity

Description	M435-1279 is a UBE2T inhibitor that blocks UBE2T-mediated degradation of RACK1, thereby inhibiting the hyperactivation of the Wnt/β-catenin signaling pathway.
In vitro	M435-1279 (0, 2, 4, 8, 16, 31 μM; 48 h) significantly inhibits the growth of AGS, HGC27, and MKN45 cells. It also inhibits cell viability with IC50s of 16.8, 11.88, 7.76, and 6.93 μM for GES-1, HGC27, AGS, and MKN45 cells, respectively. M435-1279 (31 nM to 500 μM) binds to UBE2T protein with a KD value of 50.5 μM and (11.88 μM; 48 h) blocks the ubiquitination of RACK1, thereby inhibiting the hyperactivation of the Wnt/β-catenin pathway[1].
In vivo	M435-1279 (5 mg/kg/day; intratumor injection; 18 days) inhibits tumor growth and induces increased expression of RACK1 proteins while decreasing expression of Ki-67 and β-catenin proteins in intratumor tumors[1].

Chemical Properties

Molecular Weight	419.47
Formula	C₁₈H₁₇N₃O₅S₂
Cas No.	1359431-16-5
Smiles	NS(=O)(=O)c1ccc(NC(=O)c2c(O)c3c4CCCCc4sc3[nH]c2=O)cc1
Relative Density.	1.620 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

Chloroform: < 1 mg/mL (insoluble or slightly soluble)

DMSO: 45 mg/mL (107.28 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+90% Saline: 2 mg/mL (4.77 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.3840 mL	11.9198 mL	23.8396 mL	119.1980 mL
5 mM	0.4768 mL	2.3840 mL	4.7679 mL	23.8396 mL
10 mM	0.2384 mL	1.1920 mL	2.3840 mL	11.9198 mL
20 mM	0.1192 mL	0.5960 mL	1.1920 mL	5.9599 mL
50 mM	0.0477 mL	0.2384 mL	0.4768 mL	2.3840 mL
100 mM	0.0238 mL	0.1192 mL	0.2384 mL	1.1920 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc